Diversified Trust Co Increases Position in Pfizer Inc. (NYSE:PFE)

Posted by Defense World Staff on Jun 20th, 2023

Diversified Trust Co lifted its position in shares of Pfizer Inc. (NYSE:PFE – Get Rating) by 9.8% during the 1st quarter, according to its most recent disclosure with the SEC. The firm owned 119,886 shares of the biopharmaceutical company’s stock after buying an additional 10,699 shares during the period. Diversified Trust Co’s holdings in Pfizer were worth $4,891,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also modified their holdings of PFE. Harbor Investment Advisory LLC increased its position in Pfizer by 3.6% during the fourth quarter. Harbor Investment Advisory LLC now owns 23,977 shares of the biopharmaceutical company’s stock worth $1,229,000 after purchasing an additional 825 shares during the last quarter. BancFirst Trust & Investment Management increased its position in Pfizer by 2.3% during the first quarter. BancFirst Trust & Investment Management now owns 17,794 shares of the biopharmaceutical company’s stock worth $719,000 after purchasing an additional 398 shares during the last quarter. Secure Asset Management LLC increased its position in Pfizer by 3.5% during the fourth quarter. Secure Asset Management LLC now owns 15,835 shares of the biopharmaceutical company’s stock worth $811,000 after purchasing an additional 537 shares during the last quarter. Range Financial Group LLC increased its position in Pfizer by 2.8% during the first quarter. Range Financial Group LLC now owns 37,010 shares of the biopharmaceutical company’s stock worth $1,510,000 after purchasing an additional 1,024 shares during the last quarter. Finally, Allred Capital Management LLC increased its position in Pfizer by 1.9% during the fourth quarter. Allred Capital Management LLC now owns 20,425 shares of the biopharmaceutical company’s stock worth $1,047,000 after purchasing an additional 387 shares during the last quarter. Hedge funds and other institutional investors own 67.80% of the company’s stock.

Insider Buying and Selling at Pfizer

In related news, Director Scott Gottlieb acquired 1,000 shares of Pfizer stock in a transaction on Monday, May 8th. The shares were purchased at an average cost of $38.58 per share, for a total transaction of $38,580.00. Following the purchase, the director now directly owns 6,000 shares of the company’s stock, valued at approximately $231,480. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 0.05% of the stock is currently owned by insiders.

Pfizer Price Performance

PFE opened at $40.06 on Tuesday. The company has a fifty day simple moving average of $38.92 and a 200 day simple moving average of $42.95. The firm has a market cap of $226.15 billion, a price-to-earnings ratio of 7.89, a PEG ratio of 1.33 and a beta of 0.64. Pfizer Inc. has a twelve month low of $36.17 and a twelve month high of $54.93. The company has a current ratio of 1.37, a quick ratio of 1.11 and a debt-to-equity ratio of 0.31.

Pfizer (NYSE:PFE – Get Rating) last released its quarterly earnings results on Tuesday, May 2nd. The biopharmaceutical company reported $1.23 earnings per share for the quarter, beating analysts’ consensus estimates of $1.00 by $0.23. The business had revenue of $18.28 billion during the quarter, compared to analyst estimates of $16.49 billion. Pfizer had a net margin of 31.25% and a return on equity of 37.53%. The business’s revenue was down 28.8% on a year-over-year basis. During the same period last year, the business earned $1.62 EPS. Equities research analysts expect that Pfizer Inc. will post 3.35 EPS for the current fiscal year.

Pfizer Dividend Announcement

The business also recently disclosed a quarterly dividend, which was paid on Friday, June 9th. Shareholders of record on Friday, May 12th were paid a dividend of $0.41 per share. The ex-dividend date was Thursday, May 11th. This represents a $1.64 dividend on an annualized basis and a yield of 4.09%. Pfizer’s dividend payout ratio (DPR) is 32.28%.

Wall Street Analyst Weigh In

Several equities analysts recently commented on PFE shares. Daiwa Capital Markets lowered shares of Pfizer from an “outperform” rating to a “neutral” rating and set a $38.00 price target for the company. in a research report on Thursday, May 11th. Jefferies Financial Group began coverage on shares of Pfizer in a research report on Monday, March 6th. They issued a “hold” rating and a $43.00 price objective for the company. Wells Fargo & Company dropped their price objective on shares of Pfizer from $50.00 to $44.00 and set an “equal weight” rating for the company in a research report on Friday, March 17th. Morgan Stanley dropped their price objective on shares of Pfizer from $45.00 to $44.00 and set an “equal weight” rating for the company in a research report on Monday, April 10th. Finally, Bank of America dropped their price objective on shares of Pfizer from $50.00 to $45.00 and set a “neutral” rating for the company in a research report on Friday, April 21st. Nine analysts have rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. According to MarketBeat, the stock currently has an average rating of “Hold” and a consensus target price of $47.33.

Pfizer Company Profile

(Get Rating)

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.